S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
NFLX   310.48 (-0.39%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
NFLX   310.48 (-0.39%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
NFLX   310.48 (-0.39%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
NFLX   310.48 (-0.39%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
Log in

Cytori Therapeutics Stock Price, Forecast & Analysis (NASDAQ:CYTX)

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range N/A
50-Day Range
$0.20
MA: $0.20
$0.21
52-Week Range N/A
Volume417,951 shs
Average Volume915,302 shs
Market Capitalization$4.32 million
P/E RatioN/A
Dividend YieldN/A
Beta1.96
Cytori Therapeutics, Inc is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials. The company was founded by Ralph E. Holmes and Christopher J. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CYTX
CUSIP23283K10
Phone858-458-0900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.67 million
Book Value$0.35 per share

Profitability

Net Income$-12,630,000.00
Net Margins-242.60%

Miscellaneous

Employees37
Market Cap$4.32 million
Next Earnings DateN/A
OptionableOptionable

Receive CYTX News and Ratings via Email

Sign-up to receive the latest news and ratings for CYTX and its competitors with MarketBeat's FREE daily newsletter.


Cytori Therapeutics (NASDAQ:CYTX) Frequently Asked Questions

What is Cytori Therapeutics' stock symbol?

Cytori Therapeutics trades on the NASDAQ under the ticker symbol "CYTX."

When did Cytori Therapeutics' stock split? How did Cytori Therapeutics' stock split work?

Shares of Cytori Therapeutics reverse split before market open on Thursday, May 24th 2018. The 1-10 reverse split was announced on Wednesday, May 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 23rd 2018. An investor that had 100 shares of Cytori Therapeutics stock prior to the reverse split would have 10 shares after the split.

How were Cytori Therapeutics' earnings last quarter?

Cytori Therapeutics Inc (NASDAQ:CYTX) released its quarterly earnings results on Tuesday, May, 14th. The biotechnology company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.02. The biotechnology company had revenue of $0.70 million for the quarter. Cytori Therapeutics had a negative net margin of 242.60% and a negative return on equity of 272.70%. View Cytori Therapeutics' Earnings History.

What is the consensus analysts' recommendation for Cytori Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytori Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cytori Therapeutics.

What are Wall Street analysts saying about Cytori Therapeutics stock?

Here are some recent quotes from research analysts about Cytori Therapeutics stock:
  • 1. Maxim Group analysts commented, "Cytori reported 4Q18 with product sales of $0.4M (celution system) and contract revenues of $0.7M, net loss was ($2.2M). The company ended the period with $5.3M in cash, which does not include the asset sale announced concurrently with earnings." (4/1/2019)
  • 2. According to Zacks Investment Research, "Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. " (1/15/2019)

Has Cytori Therapeutics been receiving favorable news coverage?

Press coverage about CYTX stock has trended somewhat negative recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Cytori Therapeutics earned a coverage optimism score of -1.9 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Cytori Therapeutics.

Who are some of Cytori Therapeutics' key competitors?

What other stocks do shareholders of Cytori Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytori Therapeutics investors own include Regulus Therapeutics (RGLS), Inovio Pharmaceuticals (INO), Shire (SHPG), Exelixis (EXEL), Bank of America (BAC), Athersys (ATHX), Synergy Pharmaceuticals (SGYP), BCE (BCE), Micron Technology (MU) and Idera Pharmaceuticals (IDRA).

Who are Cytori Therapeutics' key executives?

Cytori Therapeutics' management team includes the folowing people:
  • Marc H. Hedrick, President, Chief Executive Officer & Director
  • Gary S. Titus, Chief Financial Officer
  • Mark T. Marino, Chief Medical Officer & Senior Vice President
  • John K. Fraser, Chief Scientist
  • Russ Havranek, VP-Global Marketing & Business Development

How big of a company is Cytori Therapeutics?

Cytori Therapeutics has a market capitalization of $0.00 and generates $3.67 million in revenue each year. Cytori Therapeutics employs 37 workers across the globe.View Additional Information About Cytori Therapeutics.

What is Cytori Therapeutics' official website?

The official website for Cytori Therapeutics is http://www.cytori.com/.

How can I contact Cytori Therapeutics?

Cytori Therapeutics' mailing address is 3020 CALLAN ROAD, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-458-0900 or via email at [email protected]


MarketBeat Community Rating for Cytori Therapeutics (NASDAQ CYTX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  401 (Vote Outperform)
Underperform Votes:  269 (Vote Underperform)
Total Votes:  670
MarketBeat's community ratings are surveys of what our community members think about Cytori Therapeutics and other stocks. Vote "Outperform" if you believe CYTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/22/2019 by MarketBeat.com Staff

Featured Article: Sell-Side Analysts

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel